title: [New therapeutic approaches for polymyositis and dermatomyositis].
abstract: Inflammatory myopathies are chronic, immune-mediated diseases characterized with progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The aims of therapy are to increase muscle strength, prevent the development of contractures, and to manage the systemic manifestations of the disease. This is a complex treatment which requires routine and wide knowledge. The most important task is to recognize the disease and guide the patient to immunologic center. Although the first line of therapy continues to include corticosteroids, there are a multitude of agents available for treating patients with myositis. There are several different immunosuppressive agents which may be applied alone or in combination with each other, as well as an increasing number of novel and exciting biologic agents targeting molecules participating in the pathogenesis of inflammatory myopathy. Physiotherapy and rehabilitation in the remission period may significantly improve the functional outcome of patients with these disorders.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet III. Belgyógyászati Klinika, Klinikai Immunológia Tanszék, Debrecen. katalin.danko@unideb.hu
authors.forename: Katalin
authors.initials: K
authors.lastname: Dankó
authors.forename: Melinda
authors.initials: M
authors.lastname: Vincze
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods; D002465:Cell Movement / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D005081:Exercise Therapy / Q000379:methods; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D026741:Physical Therapy Modalities; D017285:Polymyositis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000187:drug effects; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate